Loading...

Chimerix

DB:CXF
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CXF
DB
$133M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The last earnings update was 47 days ago. More info.


Add to Portfolio Compare Print
  • Chimerix has significant price volatility in the past 3 months.
CXF Share Price and Events
7 Day Returns
-3.1%
DB:CXF
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-44%
DB:CXF
-10.2%
DE Biotechs
-6%
DE Market
CXF Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Chimerix (CXF) -3.1% 30.2% -2.7% -44% -58.7% -82.9%
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • CXF underperformed the Biotechs industry which returned -10.2% over the past year.
  • CXF underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
CXF
Industry
5yr Volatility vs Market

Value

 Is Chimerix undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Chimerix. This is due to cash flow or dividend data being unavailable. The share price is €2.266.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Chimerix's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Chimerix's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:CXF PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.43
NasdaqGM:CMRX Share Price ** NasdaqGM (2019-04-18) in USD $2.62
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Chimerix.

DB:CXF PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:CMRX Share Price ÷ EPS (both in USD)

= 2.62 ÷ -1.43

-1.83x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Chimerix is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Chimerix is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Chimerix's expected growth come at a high price?
Raw Data
DB:CXF PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.83x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
12.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Chimerix, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Chimerix's assets?
Raw Data
DB:CXF PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $3.50
NasdaqGM:CMRX Share Price * NasdaqGM (2019-04-18) in USD $2.62
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:CXF PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:CMRX Share Price ÷ Book Value per Share (both in USD)

= 2.62 ÷ 3.50

0.75x

* Primary Listing of Chimerix.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Chimerix is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Chimerix's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Chimerix has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Chimerix expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Chimerix expected to grow at an attractive rate?
  • Unable to compare Chimerix's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Chimerix's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Chimerix's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:CXF Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:CXF Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 12.9%
DB:CXF Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 40.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:CXF Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:CXF Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 124 -19 1
2022-12-31 74 -47 1
2021-12-31 36 -72 2
2020-12-31 25 -56 -64 2
2019-12-31 7 -62 -75 3
DB:CXF Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 7 -54 -69
2018-09-30 4 -58 -74
2018-06-30 5 -56 -75
2018-03-31 4 -55 -73
2017-12-31 4 -50 -71
2017-09-30 5 -48 -67
2017-06-30 4 -49 -66
2017-03-31 6 -49 -68
2016-12-31 6 -64 -76
2016-09-30 7 -87 -99
2016-06-30 8 -99 -115
2016-03-31 11 -110 -121

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Chimerix is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Chimerix's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:CXF Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Chimerix Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CXF Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.30 -0.30 -0.30 1.00
2022-12-31 -0.75 -0.75 -0.75 1.00
2021-12-31 -1.09 -0.98 -1.20 2.00
2020-12-31 -1.23 -1.05 -1.33 3.00
2019-12-31 -1.45 -1.25 -1.62 4.00
DB:CXF Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.43
2018-09-30 -1.54
2018-06-30 -1.58
2018-03-31 -1.55
2017-12-31 -1.51
2017-09-30 -1.43
2017-06-30 -1.43
2017-03-31 -1.46
2016-12-31 -1.65
2016-09-30 -2.15
2016-06-30 -2.48
2016-03-31 -2.69

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Chimerix will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Chimerix's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Chimerix has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Chimerix performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Chimerix's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Chimerix does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Chimerix's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Chimerix's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Chimerix's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Chimerix Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CXF Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 7.22 -69.47 23.58
2018-09-30 4.20 -73.76 26.19
2018-06-30 4.72 -74.99 27.66
2018-03-31 4.21 -73.06 27.29
2017-12-31 4.49 -70.98 27.15
2017-09-30 4.63 -66.70 25.18
2017-06-30 4.39 -66.42 24.36
2017-03-31 5.55 -67.88 24.68
2016-12-31 5.70 -76.39 25.01
2016-09-30 6.83 -99.28 28.84
2016-06-30 8.45 -114.70 31.53
2016-03-31 10.75 -121.37 32.10
2015-12-31 10.76 -117.37 31.30
2015-09-30 8.81 -99.78 26.93
2015-06-30 7.72 -84.28 24.73
2015-03-31 4.50 -71.20 20.38
2014-12-31 4.04 -59.31 17.53
2014-09-30 3.76 -47.24 13.83
2014-06-30 3.49 -36.99 9.54
2014-03-31 3.38 -46.30 8.90
2013-12-31 4.37 -70.55 8.33
2013-09-30 7.07 -68.36 7.19
2013-06-30 27.02 -55.69 7.00
2013-03-31 32.41 -35.60 6.01
2012-12-31 33.72 -8.76 6.40
2012-09-30 35.49 -8.11 4.45

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Chimerix has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Chimerix has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Chimerix improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Chimerix's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Chimerix has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Chimerix's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Chimerix's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Chimerix is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Chimerix's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Chimerix's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1315.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Chimerix Company Filings, last reported 3 months ago.

DB:CXF Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 177.60 0.14 186.53
2018-09-30 189.14 0.17 183.36
2018-06-30 191.39 0.19 174.76
2018-03-31 205.69 0.21 160.45
2017-12-31 221.81 0.22 151.52
2017-09-30 236.90 0.20 149.72
2017-06-30 249.66 0.25 148.53
2017-03-31 263.37 0.40 161.70
2016-12-31 276.22 0.44 232.02
2016-09-30 287.35 0.00 249.67
2016-06-30 299.97 0.00 272.82
2016-03-31 313.70 0.00 263.34
2015-12-31 335.46 0.35 220.33
2015-09-30 370.21 0.38 220.80
2015-06-30 399.31 1.48 258.33
2015-03-31 257.52 2.89 174.50
2014-12-31 274.64 4.30 234.58
2014-09-30 176.61 5.70 188.42
2014-06-30 190.68 7.09 200.60
2014-03-31 89.62 8.48 99.92
2013-12-31 98.54 9.87 109.98
2013-09-30 105.13 11.31 116.90
2013-06-30 111.04 12.70 123.03
2013-03-31 7.57 14.00 22.92
2012-12-31 14.20 14.62 29.76
2012-09-30 18.49 14.57 34.46
  • Chimerix's level of debt (0.1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (10% vs 0.1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Chimerix has sufficient cash runway for more than 3 years based on current free cash flow.
  • Chimerix has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -28% each year.
X
Financial health checks
We assess Chimerix's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Chimerix has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Chimerix's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Chimerix dividends. Estimated to be 0% next year.
If you bought €2,000 of Chimerix shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Chimerix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Chimerix's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:CXF Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:CXF Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Chimerix has not reported any payouts.
  • Unable to verify if Chimerix's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Chimerix's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Chimerix has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Chimerix's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Chimerix's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Chimerix afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Chimerix has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Chimerix's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Sherman
AGE 52
TENURE AS CEO 0 years
CEO Bio

Mr. Michael A. Sherman, also known as Mike, has been Chief Executive Officer of Chimerix, Inc. since April 8, 2019 and serves as President its since 2019. Mr. Sherman served as the Chief Executive Officer and President of Endocyte, Inc. since June 20, 2016. Mr. Sherman served as the Chief Financial Officer of Endocyte, Inc. since October 11, 2006 until February 2017 and its Chief Operating Officer since June 16, 2014 until June 20, 2016. He served as the Principal Accounting Officer of Endocyte, Inc., until May 26, 2011. Mr. Sherman served as a Director of Finance at Guidant Sales Corporation from March 1997 to March 2000. While at Guidant, he served several senior management positions, including Vice President for Finance and IT, Europe, Middle East, Africa and Canada and Corporate Controller and Chief Accounting Officer. He served as a Director for Corporate Financial Planning from 1994 to March 1997. He served positions in audit, domestic and international financial planning and reporting, business development and treasury while with Lilly and served as VP Finance and Strategic Planning at Guidant LLC from May 2004 to October 2006. He was a Director of Endocyte, Inc. since June 20, 2016 until December 21, 2018. He served as a Director of Mead Johnson Nutrition Company from February 26, 2015 to June 15, 2017. Mr. Sherman serves on the Indianapolis Children’s Museum Board of Trustees. He received his Masters in Business Administration from The Amos Tuck School at Dartmouth University and Graduated as a Tuck Scholar. Mr. Sherman holds a B.A. in Economics from DePauw University.

CEO Compensation
  • Insufficient data for Mike to compare compensation growth.
  • Insufficient data for Mike to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Chimerix management team in years:

4.3
Average Tenure
49
Average Age
  • The tenure for the Chimerix management team is about average.
Management Team

Tim Trost

TITLE
Senior VP
COMPENSATION
$956K
AGE
60
TENURE
8.1 yrs

William Nichols

TITLE
Chief Medical Officer
COMPENSATION
$1M
AGE
49
TENURE
4.6 yrs

Mike Sherman

TITLE
CEO & President
AGE
52

Roy Ware

TITLE
Chief Manufacturing & Technology Officer
TENURE
2.3 yrs

Randall Lanier

TITLE
Chief Science Officer
TENURE
2.3 yrs

Joe Rutledge

TITLE
VP of Information Technology & Chief Information Officer
TENURE
4.3 yrs

Michelle LaSpaluto

TITLE
Executive Director of Financial Planning
TENURE
3.3 yrs

Michael Alrutz

TITLE
Senior VP & General Counsel
AGE
48
TENURE
4.6 yrs

Mike Andriole

TITLE
Chief Business Officer
AGE
45
Board of Directors Tenure

Average tenure and age of the Chimerix board of directors in years:

4.8
Average Tenure
67
Average Age
  • The tenure for the Chimerix board of directors is about average.
Board of Directors

Martha Demski

TITLE
Chairman of the Board
COMPENSATION
$145K
AGE
65
TENURE
0.8 yrs

Pat Machado

TITLE
Director
COMPENSATION
$126K
AGE
54
TENURE
4.8 yrs

Fred Middleton

TITLE
Director
AGE
69
TENURE
1.1 yrs

Seth Rudnick

TITLE
Member of Scientific Advisory Board
AGE
69

Douglas Richman

TITLE
Member of Scientific Advisory Board

Earl Kern

TITLE
Member of Scientific Advisory Board

Michael Boeckh

TITLE
Member of Clinical Advisory Board

Raymund Razonable

TITLE
Member of Clinical Advisory Board

Jim Daly

TITLE
Director
COMPENSATION
$118K
AGE
56
TENURE
4.8 yrs

Catherine Gilliss

TITLE
Director
COMPENSATION
$117K
AGE
69
TENURE
4.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
14. Jun 18 Buy M. Berrey Individual 12. Jun 18 12. Jun 18 10,000 €3.82 €38,186
21. May 18 Sell Ernest Mario Individual 17. May 18 18. May 18 -45,000 €4.09 €-183,598
17. May 18 Sell Ernest Mario Individual 16. May 18 16. May 18 -30,000 €4.07 €-122,021
16. May 18 Sell Ernest Mario Individual 15. May 18 15. May 18 -30,000 €3.96 €-118,673
15. May 18 Sell Ernest Mario Individual 11. May 18 14. May 18 -52,553 €3.90 €-203,538
11. May 18 Sell Ernest Mario Individual 10. May 18 10. May 18 -2,815 €3.87 €-10,886
X
Management checks
We assess Chimerix's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Chimerix has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company’s lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside for the treatment of norovirus; and CMX157, a nucleoside analog for the treatment of HIV and hepatitis B virus infection. The company has license agreements with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for various antiviral indications; and Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Details
Name: Chimerix, Inc.
CXF
Exchange: DB
Founded: 2000
$118,589,379
50,903,196
Website: http://www.chimerix.com
Address: Chimerix, Inc.
2505 Meridian Parkway,
Suite 100,
Durham,
North Carolina, 27713,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM CMRX Common Stock Nasdaq Global Market US USD 11. Apr 2013
DB CXF Common Stock Deutsche Boerse AG DE EUR 11. Apr 2013
Number of employees
Current staff
Staff numbers
82
Chimerix employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:31
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/29
Last earnings filing: 2019/03/05
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.